Kane's revyve gel spray receives Health Canada approval

Executive Summary

• Kane Biotech Inc. has received Health Canada approval for its revyve anti-microbial wound gel spray, marking a significant regulatory milestone for the company's wound care portfolio in Canada.
• The approval allows clinicians and patients in Canada to access the spray for managing complex wounds, including burns, large surface area wounds, and ulcers, following its previous clearance under the US FDA 510(k) process.
• The company plans to work with healthcare partners and distributors to ensure access and education, while continuing to advance its portfolio with the recent FDA submission of a related cleanser product.

Key Details

• Regulatory Approval: Health Canada approved the revyve anti-microbial wound gel spray for use in Canada.
• Product Indication: The spray is designed to support clinicians in managing complex wounds by reducing microbial burden and promoting a healthier wound environment.
• Target Conditions: The product is indicated for managing burns, large surface area wounds, and ulcers.
• Prior Regulatory Status: The product was previously cleared under the US Food and Drug Administration (FDA) 510(k) process.
• Portfolio Context: The spray is part of the revyve wound care portfolio, which has been evaluated in multiple clinical settings in the United States.
• Upcoming Developments: Kane Biotech recently submitted revyve anti-microbial wound and skin cleanser to the FDA, which would be the third product in the revyve product line.
• Commercialization Strategy: The company intends to collaborate with healthcare partners and distributors to ensure appropriate access and education regarding the use of the spray.

Notable Quotes

• "Health Canada's approval of the revyve anti-microbial wound gel spray is another step forward in our mission to improve outcomes for patients with chronic and hard-to-heal wounds. This approval validates the strength of our clinical data and provides Canadian health care providers with a new tool to address the burden of wound infections." — Dr. Robert B. Huizinga, Interim Chief Executive Officer